Sunday, December 16, 2007
Recombinant il-2: what gives?
It has been well over a decade since the first clinical trials with recombinant interleukin-2 leads to exuberant and enduring increases in CD4 counts. Although there were toxicities with higher-dosage treatment, il-2 discoverer, Kendall Smith has published the benefits and considerably improved tolerance of low-dose il-2 treatment(pdf). Considering the fast-tracking to which anti-retroviral drugs are privy, it is quite puzzling that it has been well over a decade, and there have still been no moves toward FDA approval of interleukin-2 for AIDS treatment, and, in addition, the clinical trials drag on at a snail's pace, still testing at the less tolerable dosages to boot.